The
peptidomimetic hydroxamate
metalloproteinase inhibitor
batimastat (BB-94) was assessed for its ability to neutralize the systemic effects (lethality,
hemorrhage and coagulopathy) induced by the
venom of Bothrops asper, the most important snake from a medical standpoint in Central America.
Batimastat inhibited lethality when a
venom challenge dose of two LD(50)s was used by intraperitoneal and intravenous routes, with ED(50)s of 250 and 22 microM, respectively. With a challenge dose of three LD(50)s, lethality was not abrogated, but a conspicuous and dose-dependent delay in the time of death was observed in mice injected with mixtures of
venom plus
batimastat. Upon incubation with 500 microM
batimastat,
venom LD(50) increased 2.86-fold (intraperitoneal route) and 2.37-fold (intravenous route), when compared with LD(50) of
venom alone.
Batimastat also inhibited the hemorrhagic effect induced by
venom in the lungs after
intravenous injection. Moreover,
batimastat exerted a significant inhibition of in vitro
coagulant and in vivo defibrinogenating effects of
venom, evidencing that
metalloproteinases play a key role in the coagulopathy characteristic of B. asper envenomation. The remaining uninhibited
coagulant effect is due to
serine proteinases, i.e.
thrombin-like
enzymes, since this effect was completely abrogated by the combination of
batimastat and PMSF. Our results stress the view that
metalloproteinases play a relevant role in the systemic pathophysiology of B. asper envenomation and that
metalloproteinase inhibitors may become a therapeutic alternative in this pathology.